Skip to main content

CORRECTION article

Front. Cardiovasc. Med., 16 March 2023
Sec. Cardiovascular Metabolism
Volume 10 - 2023 | https://doi.org/10.3389/fcvm.2023.1172664

Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

This article is a correction to:

  1. The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

    1. Read original article
\r\nYasutaka Takeda Yasutaka Takeda1*Ichiro SakumaIchiro Sakuma2Shinya HiramitsuShinya Hiramitsu3Mizuho OkadaMizuho Okada4Shinichiro UedaShinichiro Ueda5Masaru Sakurai\r\nMasaru Sakurai6
  • 1Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan
  • 2Caress Sapporo Hokko Memorial Clinic, Sapporo, Japan
  • 3Hiramitsu Heart Clinic, Nagoya, Japan
  • 4Keiyukai Yoshida Hospital, Asahikawa, Japan
  • 5Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan
  • 6Department of Social and Environmental Medicine, Kanazawa Medical University, Uchinada, Japan

A Corrigendum on

The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

By Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S and Sakurai M. (2023) Front. Cardiovasc. Med. 10:1094100. doi: 10.3389/fcvm.2023.1094100

In the published article, there was an error in Table 6 (Adverse events) as published. The error was found in the percentage of participants with sepsis associated with enteritis in the PEMA group. The corrected table appears below.

TABLE 6
www.frontiersin.org

Table 6. Adverse events.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: apolipoprotein B-48, atherosclerotic cardiovascular disease, residual risk, hypertriglyceridemia, pemafibrate, polyunsaturated fatty acids

Citation: Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S and Sakurai M (2023) Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study). Front. Cardiovasc. Med. 10:1172664. doi: 10.3389/fcvm.2023.1172664

Received: 23 February 2023; Accepted: 2 March 2023;
Published: 16 March 2023.

Edited and Reviewed by: Ichiro Manabe, Chiba University, Japan

© 2023 Takeda, Sakuma, Hiramitsu, Okada, Ueda and Sakurai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yasutaka Takeda eWt0YWtlNUBhc2FoaWthd2EtbWVkLmFjLmpw

Specialty Section: This article was submitted to Cardiovascular Metabolism, a section of the journal Frontiers in Cardiovascular Medicine

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.